Nikolaus Kneidinger - Concepedia

Author

Nikolaus Kneidinger

Ludwig-Maximilians-Universität München ORCID

Also Known As

Andrew Fisher, N Kneidinger, N. Kneidinger, N., Kneidinger, Nikolas Kneidinger, Nikolaus Kneidinger, Sven Peterss

302

Publications

5.5K

Citations

H-Index

124

Concepts

All Affiliations

Ludwig-Maximilians-Universität München German Center for Lung Research LMU Klinikum Helmholtz Zentrum München Medizinische Hochschule Hannover

About

Nikolaus Kneidinger is an author at Ludwig-Maximilians-Universität München specializing in medicine, pulmonary medicine, and lung transplantation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	36	2.9K
2	Allergy	4	4	136
3	Engineering	2	2	172
4	Public Health	2	2	207
5	Health Sciences	1	1	22

Nikolaus Kneidinger

Publications

4.7K

Citations

H-Index

Page 1

	Year	Citations
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial Jürgen Behr, Antje Prasse, Michael Kreuter, The Lancet Respiratory Medicine Antifibrotic TherapyAdvanced Lung DiseaseIdiopathic Pulmonary FibrosisPulmonary PharmacologyPulmonary Fibrosis	2021	490
Hypernatremia in the Critically Ill Is an Independent Risk Factor for Mortality Gregor Lindner, Georg‐Christian Funk, Christoph Schwarz, American Journal of Kidney Diseases Critical Care MedicineAcute CarePatient SafetySepsisIndependent Risk Factor	2007	478
Hypoxic hepatitis: underlying conditions and risk factors for mortality in critically ill patients Valentin Fuhrmann, Nikolaus Kneidinger, Harald Herkner, Intensive Care Medicine Critical Care MedicineHepatologyViral HepatitisAcute CarePatient Safety	2009	204
Activation of the WNT/β-Catenin Pathway Attenuates Experimental Emphysema Nikolaus Kneidinger, Ali Önder Yildirim, Jens Callegari, American Journal of Respiratory and Critical Care Medicine	2010	193
Coagulation parameters and major bleeding in critically ill patients with cirrhosis Andreas Drolz, Thomas Horvatits, Kevin Roedl, Hepatology	2016	192
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial Marius M. Hoeper, Hikmet Al‐Hiti, Raymond L. Benza, The Lancet Respiratory Medicine HypertensionPulmonary Arterial HypertensionPhosphodiesterase-5 InhibitorsCardiovascular DiseaseMedicine	2021	151
Impact of hypoxic hepatitis on mortality in the intensive care unit Valentin Fuhrmann, Nikolaus Kneidinger, Harald Herkner, Intensive Care Medicine Critical Care ManagementCritical Care MedicineIntensive Care UnitAcute CareHepatitis	2011	130
Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery Christoph M. Zimmermann, Domizia Baldassi, Karen Y. T. Chan, Journal of Controlled Release NanoparticlesEngineeringSirna-lipid NanoparticlesNano-drug DeliveryBiomedical Engineering	2022	124
Integrative analysis of cell state changes in lung fibrosis with peripheral protein biomarkers Christoph H. Mayr, Lukas M. Simon, Gabriela Leuschner, EMBO Molecular Medicine	2021	97
Dynamics of SARS-CoV-2 shedding in the respiratory tract depends on the severity of disease in COVID-19 patients Dieter Munker, Andreas Osterman, Hans Stubbe, European Respiratory Journal	2021	92

Page 1